Author

Margaret S. Merrill

Observed name: Margaret Merrill

Institutions: Massachusetts General Hospital, Dana-Farber Cancer Institute

Observed institutions: Massachusetts General Hospital, Dana-Farber Cancer Institute

OpenAlex ID: A5031813029

Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors

2017 · Viktor A. Adalsteinsson, Gavin Ha, et al. · Nature Communications · 1,058

Prevalence, Dynamics, and Prognostic Role of Clonal Hematopoiesis of Indeterminate Potential in Patients With Breast Cancer

2024 · Stefania Morganti, Christopher J. Gibson, et al. · Journal of Clinical Oncology · 41

Identifying ERBB2 Activating Mutations in HER2-Negative Breast Cancer: Clinical Impact of Institute-Wide Genomic Testing and Enrollment in Matched Therapy Trials

2019 · Pedro Exman, Ana C. Garrido-Castro, et al. · JCO Precision Oncology · 7

Prospective Registry of Multiplex Testing (PROMPT): Follow-up.

2019 · Jamie Brower, Heather Symecko, et al. · Journal of Clinical Oncology · 2

Abstract P5-14-03: Clonal hematopoiesis of indeterminate potential after (neo)adjuvant chemotherapy versus endocrine therapy for early breast cancer: the CIRCE-eBC prospective cohort study

2023 · Stefania Morganti, Qingchun Jin, et al. · Cancer Research

Genetic testing experiences and emotional reactions among individuals with variant of uncertain significance results from cancer multiplex genetic testing.

2020 · Jada G. Hamilton, Jamie Brower, et al. · Journal of Clinical Oncology

Abstract LB-136: High concordance of whole-exome sequencing of cell-free DNA and matched biopsies enables genomic discovery in metastatic cancer

2016 · Viktor A. Adalsteinsson, Gavin Ha, et al. · Cancer Research

Works count: 7

Citation count: 1,108

H-index: 3

I10-index: 2